Our results could lead to advances in the characterization and genetic diagnosis of MUTYH-associated polyposis, consequently improving CRC prevention and the management and surveillance of these patients.
INTRODUCTION

MUTYH-associated polyposis (MAP) (OMIM #608456) is an autosomal
recessive disease that usually appears in patients with an attenuated polyposis phenotype (1, 2).This syndrome is associated with biallelic mutations in the MUTYH gene. Patients with MAP exhibit a mean of 50 polyps (3) , and this disease is responsible for 7% of attenuated adenomatous polyposis and 6.6% of classic polyposis cases (4) . MAP cases with colorectal cancer (CRC) not showing a polyposis phenotype have also been described (5) . CRC risk in patients with biallelic mutations is about 80% by the age of 70 years without treatment, and CRC is diagnosed simultaneously with the diagnosis of polyposis in approximately 50% of patients (6) . MAP patients can also present duodenal adenomatous polyps and polyps in the fundus (6, 7) . Extraintestinal neoplasias of breast, gastric, thyroid, testis, and hematologic origin have been described in MAP syndrome (8, 9) .
Two common mutations, c.536A>G; p.Y179C and c.1187G>A; p.G396D, are reportedly responsible for approximately 80% of MAP cases in Caucasian populations (2, 10) , although large deletions (11) and other low-frequency mutations have also been identified in this gene (12). The International Society for Gastrointestinal Hereditary Tumors (InSiGHT) database presently includes 300 unique DNA variants of the MUTYH gene, some of which are probable founder mutations in different populations. However, about 20-33% of the tested index patients of southern European populations do not carry one of these most common mutations (13) .
It has been recently reported that the MAP phenotype differs from other previously described polyposis syndromes in that it may involve the Author Manuscript Published OnlineFirst on January 27, 2014; DOI: 10.1158/1078-0432.CCR- coexistence of both adenomatous and serrated polyps (14) . However, to date, MAP diagnosis has been based on the presence of adenomatous polyps (4, 15, 16) . This differential phenotype makes it unclear which patients should be tested for MUTYH, and whether patients with serrated polyps or those with multiple adenomatous and serrated polyps should also be investigated for this disease. Moreover, different authors have proposed different diagnostic strategies, and no consensus has been reached (4, 5, 17, 18) .
The present study aimed to determine the prevalence of MUTYH mutations in a population of patients with multiple colonic polyps, including both adenomatous and serrated polyps, and to explore the diagnostic yield of different strategies for germline MUTYH testing in these patients. Moreover, we investigated the usefulness of somatic molecular markers in the polyps for MAP diagnosis. Our results could lead to better characterization of the syndrome and enhanced strategies for the genetic diagnosis of the disease, consequently improving CRC prevention and the management and surveillance of these patients.
Research. 
MATERIALS AND METHODS
Patients
The study included 405 patients from the EPIPOLIP study, a multicentre nationwide project that investigated causes of multiple colonic polyps and incorporated patients from 24 Spanish hospitals. Patients were retrospectively recruited during the years 2009 to 2010 (19) . Patients diagnosed with at least 10 polyps of any histology were included in the present study. Patients previously diagnosed with FAP, Lynch syndrome, or inflammatory bowel disease, and those who had only hyperplastic rectosigmoid polyps were excluded. Informed written consent was obtained from all participants. The study was approved by the Ethical Committees from the participating hospitals.
Demographic data concerning age, sex, and personal and familial history of polyposis, CRC, or other neoplasia were collected. Endoscopy reports and the corresponding histopathology reports were also reviewed to collect information about the number, size, morphology, distribution, and histology of colonic polyps. Polyps were classified as adenomatous or serrated. Polyps were considered proximal if located in the transverse or ascending colon or cecum, and distal if located in the descending or sigmoid colon or rectum. A central review of all specimens was performed by three experienced pathologists (AP, CE, and CA). Based on polyp histology, cases were classified as adenomatous polyposis, multiple adenomatous and serrated polyps, or only multiple serrated polyps (20) . Serrated polyps included hyperplastic polyps, traditional serrated adenomas, sessile serrated polyps, and mixed hyperplastic/adenomatous polyps. A total of 605 polyps were collected from 56 patients. From each polyp, we prepared nine 5-μm paraffin-embedded sections containing only the representative biopsy. Genomic DNA was extracted with the QIAamp DNA Investigator kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. All samples were dissected macroscopically by a pathologist (AP, CA, and CE) to ensure that they contained predominantly neoplastic tissue.
Germline mutation analysis
DNA sequencing
All cases were analysed by PCR and sequencing of the MUTYH exons 7 and 13, where the two most frequent mutations are located (c.536A>G; p.Y179C and c.1187G>A; p.G396D). All patients were also examined for the frame-shift change c.1227_1228dup (Glu410GlyfX43), which was previously reported as a common mutation in different Mediterranean populations (21, 22) . Patients who were heterozygous for any of these three mutations were sequenced for the whole coding region and intron-exon boundaries to determine the existence in trans, of a second mutational event. Additionally, 216 patients who showed none of the three analysed mutations were also investigated for germline mutations along the whole coding sequence of the MUTYH gene. This group was a representative sample of the initial population, with no significant Author Manuscript Published OnlineFirst on January 27, 2014; DOI: 10.1158/1078-0432.CCR- Bioinformatics tools were used to perform in silico analyses for estimating the functional effects at the RNA and protein levels of the MUTYH base substitution variants with unknown clinical significance. Polymorphism Phenotyping v2 (PolyPhen-2) and SNPs3D can predict the possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations. A PolyPhen-2 variant prediction score of below 5% was considered benign, and a score of over 95% was considered to be probably damaging. SNPs3D predictions produced support vector machine (SVM) values; values below −0.5 were associated with deleterious variants, while those over +0.5 were associated with neutral mutations. Splicing was studied using SplicePort, which predicts losses or gains of donor and acceptor splice sites. When these bioinformatics tools made at least two concordant predictions of pathogenicity for a given VUS, it was classified as clinically significant.
KRAS Gly12Cys somatic mutation analysis
Cases with polyp DNA available were tested for somatic KRAS mutation (n=56).
We analysed a mean of 10 polyps per patient. Direct sequencing was performed to identify KRAS mutation at exon 1, including codons 12 and 13. 
BRAF analysis
The V600E BRAF mutation was detected by real-time PCR (ABI PRISM 7500, Applied Biosystems, Foster City, CA, USA) using specific TaqMan probes and the allelic discrimination software (Applied Biosystems, Foster City, CA, USA), Of the 405 total patients, 183 (45.2%) had more than 10 adenomas. These patients were tested for APC mutation, and 6 cases (3.3%) showed a germline heterozygous pathogenic mutation in the APC gene. Each case with APC mutation showed exclusively adenomatous polyps.
MUTYH mutational analysis
All of the 405 patients were studied for MUTYH germline mutations. Eighteen Homozygotes carriers for each of the two common mutations did not exhibit any differences in age at diagnosis, familial history, CRC predisposition, or in the number, location, or size of polyps. However, serrated polyps were more common in p.G396D homozygotes carriers (83.3%) than in p.Y179D homozygotes carriers (0%) (chi-square, p=0.05). Four (50%) compound heterozygous cases showed only adenomatous polyps, while the remaining four showed both adenomas and serrated polyps. The mean ages at diagnosis were 47 (homozygous p.Y179C), 57 (homozygous p.G396D), and 57 years (heterozygous p.Y179C/ p.G396D), indicating that homozygous mutations in Y179C were associated with early onset of MAP syndrome (chi-square, p=0.05). Nineteen monoallelic carriers of any of the three most common mutations were found, including 7 monoallelic carriers for the Y179C mutation, 10 for the G396D mutation, and 2 for the c.1227_1228dup mutation.
Whole MUTYH gene study
We performed whole-gene analysis for the 19 patients who were heterozygous for any of the three common mutations. Nine of these patients (47.4%) showed a second MUTYH mutation, including three that had been previously described as pathogenic (the nonsense pathogenic mutation Gln338X, the known pathogenic changes c.389-1G>A and c.721C>T) (24, 25 
three were classified as pathogenic based on the predictions of in silico studies (table 2) . Therefore, another six patients were genetically diagnosed with MAP ( figure 1, group 2; table 1) .
Whole-gene analysis was also performed in a representative sample of 216 patients who did not show any of the three recurrent mutations. Only one of these patients (0.5%) had a biallelic pathogenic MUTYH mutation. This patient (table 1, # 27) was diagnosed at 40 years of age, and had one brother who was also diagnosed with polyposis at 40 years of age; no genotyping data was accessible for this relative.
Another patient exhibited two concurrent VUS, both considered to be likely benign. Whole-gene analysis also identified seven patients as heterozygous, but only one VUS identified in these patients was classified as probably pathogenic based on the in silico results. No large rearrangements were identified in these patients (tables 1 and 2).
Clinical and pathological features of MAP patients
Overall, a total of 27 patients were diagnosed with MAP due to biallelic pathogenic mutations (tables 1 and 3) , indicating an estimated 6.7% prevalence of MAP among APC mutation-negative cases with multiple polyps in the colon (27 out of 405). Of these 27 patients, 16 (59.3%) had CRC, and serrated polyps were found in 11 (40.8%). One patient fulfilled the WHO criteria for serrated polyposis ( Comparing patients with biallelic mutations in the two common MUTYH hotspots (group 1) with those carrying other pathogenic mutations (group 2) revealed no significant differences in age at diagnosis; total number, size, and location of polyps; presence of serrated polyps; familial history; extracolonic cancer; or CRC predisposition (table 4). However, there was a trend for patients of group 2 to have an earlier age at diagnosis (48.5 vs. 54.8 years).
MAP patients who carried the G396D mutation showed older age at diagnosis, and this mutation was significantly associated with the presence of 
KRAS c.34G>T and BRAF V600E somatic mutation analysis
A total of 605 polyps from 56 patients included in this study were analysed for the KRAS Gly12Cys and BRAF V600E somatic mutations. According to histology, 50.2% of the polyps were classified as tubular adenomas, 9.5% as tubulovillous adenomas, and 40.3% as serrated polyps. Among MAP patients, 10 .3% of polyps were serrated, whereas 58.7% were serrated in MUTYHnegative patients Polyps from 13 MAP patients were analysed for the KRAS Gly12Cys somatic mutation. Eleven of these patients (84.6%) showed this mutation in at least 10% of their polyps (mean, 29%; range, 10%-50%) (tables 1 and 2) . One of the five carriers of heterozygous MUTYH mutations showed the KRAS Gly12Cys mutation in 50% of polyps. This mutation was not observed in any of the 373 polyps from 36 MUTYH-negative patients, or in the two patients who carried benign VUS. Comparing MAP cases with those without MUTYH mutation revealed a strong association between germinal MUTYH mutation and KRAS Gly12Cys somatic mutation in polyps (p<0.001) (table 3). KRAS Gly12Cys somatic mutation was found more frequently in serrated polyps and tubulovillous adenomas (61.5% and 63.6%, respectively) than in tubular adenomas (14%) (p<0.001). Gly12Cys mutation was more frequent in larger polyps (>5 mm): 38.1% vs. 19.3% (p=0.02). No differences were found relating to polyp location. On the other hand, BRAF V600E mutation was not detected in any of the 178 analysed polyps from MAP patients, and was detected in 31.2% (116 out of 373) of polyps from MUTYH-negative patients. BRAF mutation was predominantly found in serrated polyps (table 3).
Performance of different strategies for MAP diagnosis
We found that only 18 out of 27 (66.6%) MAP cases could be explained by biallelic mutations in the two common MUTYH hotspots. Analysis of the two hotspots and the third common variant in our population resulted in a sensitivity of 74.1% (20 out of 27 cases). Whole-gene analysis of cases heterozygous for any of the three common variants achieved the best performance, diagnosing 96.3% of cases. Table 5 shows the performance characteristics of these strategies.
Considering the characteristics of our MAP patients, investigation of the MUTYH gene in cases with only adenomatous polyps would achieve a sensitivity of only 59.3%. If we had performed the MUTYH study in only patients with more than 30 adenomas, 10 patients with MAP (37%) would not have been identified. However, by including patients with multiple adenomatous and serrated polyps and more than 10 adenomas, only one patient would remain undiagnosed ( 
DISCUSSION
The present report describes several notable results. First, almost half of the identified MAP cases showed both adenomatous and serrated polyps, especially when G396D mutation was involved. There were even cases showing less than 10 adenomas, raising the question of whether there is an adenoma cut-off for MAP diagnosis in cases with both adenomatous and serrated polyps. Second, we found that the MAP diagnostic strategy should start with analysis of the most common mutations, taking into account locally prevalent mutations, and it should include whole-gene analysis only in cases that present a heterozygous mutation in a gene hotspot. Third, in our population, the majority of MUTYH mutation carriers showed the somatic KRAS Gly12Cys mutation in their polyps, but BRAF V600E mutation was not found in serrated polyps of MAP patients.
Biallelic germline mutations in MUTYH accounted for 6.7% of the analysed cases that had an attenuated polyposis phenotype. This mutation detection rate was lower than found in previous reports (2, 22, 26, 27) , but similar to that described in more recent studies of cases with multiple colorectal adenomas (4).The frequencies of the Y179C and G396D alleles were consistent with those in previous studies (10, 22, 28) , although the present population showed a higher heterogeneity of MUTYH mutations-including 10 new variants, five of which were considered pathogenic. Our study confirms previous reports 
serrated polyps throughout the colon, especially when familial history suggests a recessive hereditary pattern, and in patients who are young or who have a high number of polyps. We found one MAP patient fulfilling the WHO criteria for serrated polyposis (20) , which represents a 2.5% of patients with serrated polyposis included in the study, supporting the need for studies of MUTYH in patients with this disease (14) .
Massive parallel sequencing methodologies are undoubtedly going to change the analysis strategy in cancer genetics; however, until next generation sequencing becomes broadly available in diagnostic laboratories, Sanger sequencing remains essential. Our present findings have important implications for the design of mutation detection strategies. We recommend a sequential analysis strategy using the direct sequencing of exons 7 and 13 of MUTYH for MAP diagnosis, starting with examination of the most locally prevalent mutations. In our study, more than 95% of diagnosed MAP cases had at least one of the three most common mutations, which were all located in these exons. Correct MAP diagnosis requires identification of the locally prevalent mutations that exist in a large proportion of cases with MUTYH germline mutation by analysing the whole gene in a number of cases. Our results support the need for complete MUTYH gene analysis only in patients who are carriers of prevalent mutations (Y179C, G396D, and Glu410GlyfX43), even if recessive inheritance is not confirmed. We found a very low diagnostic yield from wholegene analysis in patients with multiple adenomatous and serrated polyps. No MUTYH rearrangements were identified in this study. Not having analysed the whole gene in every case was a limitation of our study, which precludes the possibility of having more accurate values for the sensitivity and specificity of 
the different strategies. However, given the extremely low rate of biallelic pathogenic mutation found in the 216 studied cases, we decided not to complete the whole-gene testing in all cases.
It has been suggested that there is a genotype-phenotype association for MUTYH mutations, with worse pathogenicity and earlier age of onset in carriers of the Y179C allele (29) . Our results offer new insight into this association. We report that the G396D variant was strongly associated with the presence of serrated polyps, even in heterozygosis. We also found two patients who developed endometrial cancer; one had a sister with MUTYH biallelic mutation who also had both endometrial and colorectal cancer. Endometrial cancer has been proposed as an extracolonic neoplasia in MAP syndrome (30) , and the present findings might support this partnership. However the number of MAP cases that we included precludes our ability to provide solid evidence regarding the association between MAP and extracolonic neoplasms. Table 5 . Performance characteristics of selected strategies for identification of patients with MAP* *Performance characteristics were calculated based on the 255 patients subjected to whole-gene analysis (216 lacking the three most common mutations, 13 with only monoallelic mutation, and 20 with biallelic mutation in common variants) 
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